Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
Teva Pharmaceuticals (TEVA) has received a credit rating upgrade from Moody's Investor Services, raising the company's corporate credit rating to Ba1 with a stable outlook from Ba2 with a positive outlook. The upgrade reflects Teva's significant global presence, growth in branded franchises, stabilization of its generics business, and successful debt reduction efforts. According to CFO Eli Kalif, this upgrade validates the success of Teva's Pivot to Growth strategy and is expected to result in improved debt costs and broader access to investors.
Teva Pharmaceuticals (TEVA) ha ricevuto un aumento del rating creditizio da Moody's Investor Services, che ha portato il rating aziendale a Ba1 con outlook stabile da Ba2 con outlook positivo. Questo miglioramento riflette la significativa presenza globale di Teva, la crescita delle sue linee di prodotti a marchio, la stabilizzazione del settore dei generici e i successi nella riduzione del debito. Secondo il CFO Eli Kalif, questo upgrade conferma il successo della strategia Pivot to Growth di Teva e si prevede che comporterà costi del debito più bassi e un accesso più ampio agli investitori.
Teva Pharmaceuticals (TEVA) ha recibido una mejora en su calificación crediticia por parte de Moody's Investor Services, elevando la calificación corporativa a Ba1 con perspectiva estable desde Ba2 con perspectiva positiva. La mejora refleja la significativa presencia global de Teva, el crecimiento de sus franquicias de marca, la estabilización de su negocio de genéricos y los exitosos esfuerzos para reducir la deuda. Según el CFO Eli Kalif, esta mejora valida el éxito de la estrategia Pivot to Growth de Teva y se espera que resulte en menores costos de deuda y un acceso más amplio a los inversores.
테바 제약회사(TEVA)는 무디스 투자자 서비스로부터 신용 등급이 상향 조정되어 회사의 기업 신용 등급이 Ba2에서 Ba1, 안정적 전망으로 변경되었습니다. 이번 등급 상향은 테바의 글로벌 입지 강화, 브랜드 프랜차이즈 성장, 제네릭 사업의 안정화, 그리고 성공적인 부채 감축 노력을 반영합니다. CFO인 엘리 칼리프는 이번 상향 조정이 테바의 Pivot to Growth 전략의 성공을 입증하며, 부채 비용 절감과 투자자 접근성 확대에 기여할 것으로 기대한다고 밝혔습니다.
Teva Pharmaceuticals (TEVA) a reçu une amélioration de sa note de crédit par Moody's Investor Services, portant la note d'entreprise à Ba1 avec une perspective stable contre Ba2 avec une perspective positive auparavant. Cette amélioration reflète la présence mondiale significative de Teva, la croissance de ses franchises de marques, la stabilisation de son activité générique et les efforts réussis de réduction de la dette. Selon le CFO Eli Kalif, cette revalorisation confirme le succès de la stratégie Pivot to Growth de Teva et devrait entraîner une réduction des coûts de la dette ainsi qu'un accès élargi aux investisseurs.
Teva Pharmaceuticals (TEVA) hat von Moody's Investor Services ein Rating-Upgrade erhalten, wodurch das Unternehmens-Rating von Ba2 mit positivem Ausblick auf Ba1 mit stabilem Ausblick angehoben wurde. Das Upgrade spiegelt Tevas bedeutende globale Präsenz, das Wachstum der Markenfranchises, die Stabilisierung des Generikageschäfts und erfolgreiche Schuldenabbau-Maßnahmen wider. Laut CFO Eli Kalif bestätigt dieses Upgrade den Erfolg der Pivot to Growth-Strategie von Teva und wird voraussichtlich zu verbesserten Finanzierungskosten und einem breiteren Zugang zu Investoren führen.
- Credit rating upgrade to Ba1 from Ba2 by Moody's
- Growth in branded franchises showing positive momentum
- Stabilization achieved in generics business
- Expected reduction in cost of debt
- Improved access to investor base
- None.
TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Moody's Investor Services (“Moody's”) has raised the company's corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive.
Moody's report cites the Company's strengths which include significant global scale, ongoing growth in the company’s branded franchises, stabilization of the company’s generics business, focus on debt reduction and resolution of various legal liabilities https://ratings.moodys.com/ratings-news/443085.
“This is a testament to the consistent performance of Teva as a result of the company’s Pivot to Growth strategy,” said Eli Kalif, Chief Financial Officer, Teva Pharmaceuticals. “This upgrade is expected to improve both our cost of debt, and our access to an enhanced base of investors.”
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva’s commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. We are dedicated to addressing patients’ needs, now and in the future. Moving forward together with science that treats, inspired by the people we serve. To learn more about how Teva is all in for better health, visit www.tevapharm.com.
Teva Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned “Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
| Teva Media Inquiries | TevaCommunicationsNorthAmerica@tevapharm.com |
| Teva Investor Relations Inquiries | TevaIR@Tevapharm.com |
FAQ
What is TEVA's new credit rating from Moody's in 2025?
How will the Moody's rating upgrade benefit TEVA?
What factors led to TEVA's credit rating upgrade?
What is TEVA's Pivot to Growth strategy achieving?
